In non–small cell lung cancer patients treated with anti-PD-1/PD-L1 antibodies, the ESPILoN score [smoking history, liver metastasis, lactate dehydrogenase (LDH), and neutrophil to lymphocyte ratio (NLR)], the Gustave Roussy Immune Score (GRIm-Score) (LDH, serum albumin (Alb), and NLR) and the RHM score (LDH, Alb, and the number of metastatic sites) was reported to be significantly correlated with prognosis14–16. This evidence concerns the gene ALB and lung cancer.